The Effects of Cumulative Dose and Polymorphisms in CYP2B6 on the Mitotane Plasma Trough Concentrations in Chinese Patients With Advanced Adrenocortical Carcinoma

Mitotane is the only drug approved to treat adrenocortical carcinoma (ACC), and a relationship of pharmacokinetic/pharmacodynamic has been characterized. However, limited evidence concerning affecting factors in large interindividual variability of the pharmacokinetics of mitotane is available. To a...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Xin, Shang, Junmei, Fu, Qiang, Lu, Lin, Deng, Jianhua, Tang, Yan, Li, Jiantao, Mei, Dan, Zhang, Bo, Zhang, Shuyang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9281498/
https://www.ncbi.nlm.nih.gov/pubmed/35847963
http://dx.doi.org/10.3389/fonc.2022.919027

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9281498/
https://www.ncbi.nlm.nih.gov/pubmed/35847963
http://dx.doi.org/10.3389/fonc.2022.919027

Ejemplares similares